Echosens

09/09/2025

Today, we had the honor of welcoming Michael Betel, President and Founder of the Fatty Liver Alliance, to our Paris offices.

As part of our “My Health, My Liver” internal campaign, Michael shared his perspective on advancing liver disease care and policy. His advocacy for patient-centered care, early screening, and expanded treatment options is inspiring and impactful worldwide.

🙏 A big thank you to Michael for joining us. Echosens is proud to partner with the Fatty Liver Alliance as we work together to advance liver health globally.

08/09/2025

✨Exciting news in liver health: the FDA has accepted Echosens’ Letter of Intent to qualify LSM by VCTE (FibroScan®) as the first non-invasive surrogate endpoint in MASH clinical trials.

This milestone opens a path for FibroScan® to ultimately replace liver biopsy for patient enrollment and treatment response assessment in MASH drug development—making participation in clinical trials less burdensome and more accessible for people living with advanced steatotic liver disease.

Read our press release for full details: https://www.prnewswire.com/apac/news-releases/fda-accepts-letter-of-intent-to-qualify-lsm-by-vcte-fibroscan-as-first-non-invasive-surrogate-endpoint-in-mash-clinical-trials-302548105.html?tc=eml_cleartime

08/09/2025

🔥Last chance to register to our - Beyond the Numbers: FibroScan® Insights for Management.

🩺 The leading expert Pr. William Alazawi will share his experience on how liver stiffness and liver steatosis measurements (LSM by VCTE™ and CAP™) can guide for effective and confident decisions in the management of MASLD.

🧭 Agenda Highlights:
• Guided VCTE™ Overview – What it measures and how it enhances FibroScan® performance
• Making Sense of FibroScan® Results – Thresholds, scoring tools, and practical insights
• Utility of Fast, Agile 3 and Agile 4 Scores in results interpretation.
• Case Studies – 2–3 patient scenarios with discussion on interpretation and action
• Live Q&A – Addressing your key questions

📅 Tomorrow at 6 PM !

💡 Don’t miss thTake your liver health expertise to the next level by registering today : https://event.on24.com/wcc/r/4966331/4BA0DC98D7B5C4EF80EAE43BABD1906B?partnerref=facebook

04/09/2025

For primary care physician, Jinsong Zhang, MD, PhD, the biggest hurdle in managing steatotic liver disease isn’t treatment—it’s patient awareness and motivation.

“When patients don’t feel symptoms and see no evidence of illness, they have no reason to take action. Many of the patients I see early on like the way they look; they’re happy with their lifestyles, and they enjoy the habits that may have led them to this situation. The fact is, as few as 5% of people with metabolic dysfunction-associated steatotic liver disease (MASLD) know they have the disease.”

🧭 Dr. Zhang says that using objective, quantitative FibroScan® data is the best way to convince people to take their liver health seriously. He likens it to giving them a GPS for their health. “The numbers are eye-opening for almost every patient, and they’re powerful benchmarks I can use later to navigate progress and keep them motivated.”

29/08/2025

🌟 The FDA approval of Wegovy® for MASH is indeed historic and to be celebrated—but it’s only step one. The real breakthrough will come when liver health is treated as core to metabolic care, with earlier detection and broader access to non-invasive tools.

Jon Gingrich, CEO of Echosens North America, shares what he believes must come next in MedCity News. Read it here: https://medcitynews.com/2025/08/after-wegovys-historic-mash-approval-whats-next/

Approval is only the beginning. Now comes the harder part: identifying the right patients, detecting the disease earlier, and monitoring outcomes so that this promising treatment is effective at scale.

26/08/2025

📺Join us for our upcoming - Beyond the Numbers: FibroScan® Insights for Management.

🩺 The leading expert Pr. William Alazawi will share his experience on how liver stiffness and liver steatosis measurements (LSM by VCTE™ and CAP™) can guide for effective and confident decisions in the management of MASLD. This practical and clinically oriented session designed for physicians managing patients with metabolic liver disease.

✅ Why attend?
• Get a clear overview of Guided VCTE™ and how it enhances FibroScan® performance.
• Learn to interpret key parameters: Liver Stiffness Measurement (LSM), CAP™, with the support of Fast and Agile Scores.
• Review real-world case studies in MASLD/MASH, from diagnosis to follow-up.
• Participate in a live Q&A session with expert answers to your clinical questions.

📅 Tuesday, September 9th
🕕 6:00–7:00 PM (London Time)

Take your liver health expertise to the next level by registering today: https://event.on24.com/wcc/r/4966331/4BA0DC98D7B5C4EF80EAE43BABD1906B?partnerref=facebook

20/08/2025

🚨 Exciting news in liver health: The European Commission has approved Rezdiffra™ (resmetirom)—the first medication approved for people living with MASH in the European Union. Congratulations, Madrigal Pharmaceuticals!

At Echosens, we are proud to support the ongoing Phase 3 MAESTRO-NASH program, where the proprietary biomarkers of FibroScan® (LSM by VCTE™ and CAP™) play a key role in both identifying patients for treatment and measuring therapeutic response after 52 weeks.

This milestone highlights the critical role of non-invasive tools in advancing earlier diagnosis, ongoing monitoring, and improved outcomes for patients.

19/08/2025

Metabolic dysfunction-associated steatohepatitis (MASH) affects an estimated 1 in 20 people globally, yet 90% remain undiagnosed. Without intervention, it can progress to advanced fibrosis, cirrhosis, liver failure—and dramatically increase risks for heart attack, stroke, and type 2 diabetes.

With the FDA approval of Wegovy® for MASH, timely diagnosis is more important than ever. You can’t treat what you don’t diagnose.

FibroScan® provides a quick, painless, point-of-care assessment in as little as 4 minutes, helping providers detect disease early, guide treatment decisions, and monitor progress with precision.

Together with Novo Nordisk, we’re working to double diagnostic rates for advanced to severe MASH by 2027—because earlier care means better outcomes for patients.

Read our press release here: https://www.prnewswire.com/news-releases/echosens-and-novo-nordisk-advance-partnership-to-increase-awareness-and-early-diagnosis-of-mash-302531721.html

/PRNewswire/ -- Echosens, the leader in non-invasive liver diagnostics, and Novo Nordisk are strengthening their aligned efforts to combat steatotic liver...

18/08/2025

👏 Congratulations to Novo Nordisk on its FDA approval of Wegovy® (semaglutide) as the first GLP-1 therapy for metabolic dysfunction-associated steatohepatitis (MASH). This is a landmark achievement for liver health and the millions of people living with this silent, dangerous disease.

Echosens is proud to advance our long-standing partnership with Novo Nordisk to accelerate early diagnosis, improve access to care, and support better outcomes through FibroScan®—the leading non-invasive tool for identifying and monitoring steatotic liver disease.

As treatment options expand, so does the need for scalable, cost-effective, point-of-care diagnostics. FibroScan is already helping providers document medical necessity and make confident, timely treatment decisions, including in Novo Nordisk’s ESSENCE trial.

This is more than an approval—it’s a new chapter for metabolic health.

Read our press release here: https://www.prnewswire.com/news-releases/echosens-and-novo-nordisk-advance-partnership-to-increase-awareness-and-early-diagnosis-of-mash-302531721.html

13/08/2025

🎉Today we celebrate a special milestone with Neighborhealth (previously East Boston Neighborhood Health Center). They have successfully used FibroScan® to screen and monitor over 1500 patients at-risk for liver disease! Together, we are shaping the future of liver health by monitoring patients with MASLD early!

🫱🏻‍🫲🏻Thank you for uniting with Echosens on the fight against MASLD. We look forward to many more milestones to come!

➡️ Know a practice that is leading the way in liver care? We’d love to hear about them!

11/08/2025

🚨 Insulin resistance doesn’t begin with type 2 diabetes.

🎥 Endocrinologist Martin Grajower, MD reminds us that prediabetes, metabolic syndrome, PCOS—and the silent cardiovascular risks they carry—all fall under the same metabolic umbrella.

👩‍⚕️👨‍⚕️ Providers: If you're managing metabolic disease, you're also managing the most common form of liver disease, whether you realize it or not. It’s time to treat liver health as a frontline concern in cardiometabolic care.

24/07/2025

Echosens is proud to shine a spotlight on practices that are transforming liver health with FibroScan®. Our is united in the same mission: to provide access to liver health assessment for all.

🤗 Thank you, KC Care, for your dedication to patients at risk of liver disease and welcome to the !

➡️Tag your practice that is leading the way in liver health. We’d love to hear your story!